Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of approximately 4,222,288 shares of its common stock. The company expects gross proceeds of approximately … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Announces $7.4M Registered Direct Offering”
Definitive agreements with institutional, accredited investors call for issuance and sale of more than 3.5 million shares of common stock POAI currently focused on applying AI to develop personalized medical treatments, novel lab media and improved vaccines One of POAI’s highest priorities is building multi-omic predictive models of tumor drug response and outcome Predictive Oncology … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Enters into Definitive Agreements for Direct Offering Totaling Estimated $3 Million”
Precision medicine in oncology allows for clinicians to develop personalized cancer treatment plans using individual characteristics of each patient Doctors use insights drawn from laboratory-grown cancer cells, patients’ DNA to individualize cancer treatment Predictive Oncology has been forerunner in its field, both through Helomics division’s smart tumor profiling platform as well as TumorGenesis subsidiary, which … Continue reading “Predictive Oncology Inc. (NASDAQ: POAI) Stands to Benefit from Explosive Growth of Precision Medicine”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced that it will start an in-house drug repurposing project, focused on ovarian cancer, using its proprietary AI-driven, patient centric discovery platform – PeDAL(TM). The project will use PeDAL to rapidly and cost-effectively profile panel … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc.’s (NASDAQ: POAI) Helomics Launches Project Focused on Ovarian Cancer Utilizing Proprietary PeDAL(TM) Platform”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has received a letter from the Listing Qualifications Department of the Nasdaq Stock Market Inc. (NASDAQ). The letter informed Predictive Oncology that the company had regained compliance with the minimum bid price requirement set forth in … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, has been rated as a “Buy” in the first analyst coverage report released by equity research firm Litchfield Hills Research LLC. POAI was listed as a “Buy” under the report’s three-tiered (buy, hold, sell) rating system. … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Ranked as Buy in Litchfield Hills Recent Analyst Report”
Ovarian cancer is a leading cause of death, causes more death than any other female reproductive system cancer POAI’s Helomics dedicated to improving clinical decision making for ovarian cancer patients Helomics has pioneered testing of drugs on patients’ own tumors to help oncologists individualize treatment options According to the American Cancer Society, an estimated 21,750 … Continue reading “Predictive Oncology (NASDAQ: POAI) Subsidiary Working to Individualize, Improve Ovarian Cancer Treatment Options”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced a contract between its wholly owned subsidiary, Soluble Biotech Inc., with a large pharmaceutical company. According to the update, the work will involve using Soluble Biotech’s proprietary protein formulation technology to improve the solubility … Continue reading “NetworkNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Enters Strategic Contract with Large Pharmaceutical Company”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed of its previously announced registered direct offering. The offering comprised 3,414,970 shares of POAI’s common stock, offered at a purchase price of $1.20 per share, which was priced at-the-market under Nasdaq rules. … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $4.1 Million”
Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced that it has closed on its previously announced registered direct offering; the company also announced that it has completed definitive agreements with a number of institutional and accredited investors for a registered direct offering. According … Continue reading “NetworkNewsBreaks – Predictive Oncology (NASDAQ: POAI) Closes Registered Direct Offering for $2.2 Million, Announces $4.1 Million Registered Direct Offering”